subscribeSubscribe
EU approves AstraZeneca’s Tagrisso as new 1st-line treatment for lung cancer

EU approves AstraZeneca’s Tagrisso as new 1st-line treatment for lung cancer
PHARMABIZ
06 Jul 2024
Share Share
China approves AZ`s Tagrisso-chemo combo as first-line treatment

China approves AZ`s Tagrisso-chemo combo as first-line treatment
REUTERS
26 Jun 2024
Share Share
Tagrisso granted Priority Review in the US for patients with unresectable

Tagrisso granted Priority Review in the US for patients with unresectable
PHARMABIZ
10 Jun 2024
Share Share
TAGRISSO Reduces Progression Risk By 84% In Unresectable EGFR+ NSCLC

TAGRISSO Reduces Progression Risk By 84% In Unresectable EGFR+ NSCLC
BUSINESSWIRE
02 Jun 2024
Share Share
AstraZeneca aims for $80 bln in total revenue by 2030

AstraZeneca aims for $80 bln in total revenue by 2030
REUTERS
21 May 2024
Share Share
Jury says AstraZeneca should pay Pfizer $107M+ over Tagrisso infringement

Jury says AstraZeneca should pay Pfizer $107M+ over Tagrisso infringement
Nicole DeFeudis ENDPTS
20 May 2024
Share Share
Pfizer wins $107.5M from AZ in US cancer drug patent trial

Pfizer wins $107.5M from AZ in US cancer drug patent trial
Blake Brittain REUTERS
18 May 2024
Share Share
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth

AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
Jonathan Gardner BIOPHARMADIVE
26 Apr 2024
Share Share
AstraZeneca beats revenue, profit estimates on resilient demand

AstraZeneca beats revenue, profit estimates on resilient demand
REUTERS
25 Apr 2024
Share Share
TAGRISSO demonstrated efficacy benefit in EGFR-mutated lung cancer

TAGRISSO demonstrated efficacy benefit in EGFR-mutated lung cancer
BUSINESSWIRE
20 Feb 2024
Share Share